A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.

@article{Dong2011ASI,
  title={A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.},
  author={Jianying Dong and Arlene J Sereno and Dikran A Aivazian and Emma Langley and Brian R Miller and William B. Snyder and Eric Lap-Shing Chan and Matt Cantele and Ronald Morena and Ingrid B. J. K. Joseph and Antonio D. Boccia and Cyrus Virata and James Gamez and Grace Yco and Michael Favis and Xiufeng Wu and Christilyn P. Graff and Qin Wang and Ellen Rohde and Rachel Rennard and Lisa Berquist and Flora Huang and Ying Zhang and Sharon X Gao and Steffan N. Ho and Stephen J. Demarest and M. E. Reff and Kandasamy Hariharan and Scott M Glaser},
  journal={mAbs},
  year={2011},
  volume={3 3},
  pages={273-88}
}
The epidermal growth factor receptor (EGFR) and the type I insulin-like growth factor receptor (IGF-1R) are two cell surface receptor tyrosine kinases known to cooperate to promote tumor progression and drug resistance. Combined blockade of EGFR and IGF-1R has shown improved anti-tumor activity in preclinical models. Here, we report the characterization of a stable IgG-like bispecific antibody (BsAb) dual-targeting EGFR and IGF-1R that was developed for cancer therapy. The BsAb molecule (EI-04… CONTINUE READING